The Blue Cross Blue Shield Association (BCBSA) has partnered with Onduo, a diabetes management company created by Verily (an Alphabet Company) and Sanofi, on a pilot program that will provide eligible members with access to personalized and convenient diabetes care. The pilot is designed to measure type 2 diabetes outcomes including those relating to clinical improvement, cost and member experience. Pilots will begin in the first quarter of 2018 in Arkansas, Georgia and South Carolina with select Blue Cross and Blue Shield (BCBS) members who are eligible.
"Blue Cross and Blue Shield companies have a long history of bringing locally tailored, innovative programs to the communities we serve," Jody Voss, vice president of development, innovation and the group purchasing organization for BCBSA, said in a statement. "We are pleased to be able to continue this tradition by partnering with Onduo on a new diabetes management program that will help eligible members better manage their type 2 diabetes."
The Onduo platform integrates hardware and software to provide people with access to personalized, convenient diabetes care. Participating BCBS members will be matched to the clinically appropriate interventions including wirelessly-connected continuous glucose monitoring devices, lifestyle support, medication review and a team of Onduo health care experts.
The program aims to provide care and support to members when and where they want it. In this way, the Onduo platform will extend physicians' support by providing guidance and continuous support to members between doctor visits.
"Onduo's goal is to increase access to solid, evidence-based interventions in a personalized manner. Managing diabetes is a 24/7 job that we want to make easier for members," Josh Riff, CEO of Onduo, said in a statement. "We are thrilled to partner with the Blue Cross Blue Shield Association to help members receive the support and care they need to become healthier."
According to the Blue Cross and Blue Shield Health Index, diabetes ranks third nationally for its impact on the quality of life and cost for the commercially insured population among more than 200 common diseases and health conditions.